Antiverse · Homepage Wireframe · Rev 04
Discuss your target Partnership options
Doc AV-001 Rev 04 Class GPCR / Ion channel Status Accepting targets Series A closed at $9.3M
Convergent Drug Design

Designing antibodies others can't reach.

Everyone in this field promises speed. We write the number down.

Submit a target Partnership options
Hero, post-audit. Every benchmark site leads with ambition and no arithmetic. The spec panel is the differentiator: numbers above the fold, in a category that has none.
Programme specificationAV-001
Delivery6 months
InputTarget structure only
OutputFunctional lead panel
Validation400+ proprietary cell lines
Track recordTop 15 & Top 20 Pharma
Feasibility48-hour written response
Trusted by
Nxera GlobalBio Amgen CF Foundation Top 15 Pharma Top 20 Pharma
6
Partner programmes
delivered to date
2
Top-20 pharma
partners
$9.3M
Series A,
closed
7 yrs
GPCR-exclusive
training data
Social proof, immediately below the fold — strategy §Homepage Restructure. Partner logos, funding and track record in the first screen after the hero. Anonymised tiers stand in until case-study sign-offs land; each one becomes a named logo as permissions come through.
01The problem

A target sits on the list
for four years.

Not because the biology is unclear. Because nobody can say what it costs to find out.

400+
Receptors implicated in human disease
3
FDA-approved antibodies against the class
0
Approved antibodies against ion channels
Opens on the buyer's decision, not the platform — strategy §What's Wrong Today. The language gap is the biggest barrier to closing partnerships. An executive needs the size of the unclaimed prize, not the mechanism.

You cannot screen for something you cannot see.

02The obstacle

Screening finds only what already exists.

These binding sites are small and buried. If nothing in the library fits, the screen returns nothing — and the target gets blamed for the method.

Library against pocket
NO FIT
Strategy §The Narrative Problem. The doc's iceberg and forest metaphors communicate difficulty without mastery. Naming the obstacle precisely lets the turn land as a solved problem.
03The category's answer

Everyone says faster.
Nobody says when.

Live homepage claims from the companies competing for the same pharma budget.

CompanyHomepage promiseFalsifiable?
GenerateGenerative biology. Unprecedented speed and success rates.No number
AbCelleraA mission about caring for people who will need medicines.No number
BigHatBetter biologics faster, through ML-guided design.No number
NablaDesigning better medicines. Making drug development designable.No number
NxeraOur life's work, is life itself.No number
AntiverseSix months from target to functional candidates.Yes
Built on live evidence. I read all five homepages. None states a timeline or falsifiable claim above the fold, while a VP of External Innovation evaluates exactly that.

Client decision: naming competitors is Murat's call. If legal objects, soften to "a leading AI biotech" — the argument survives without the names, not without the contrast.

So we stopped screening, and built the thing nobody can buy.

04The edge

Design is now table stakes.
The wet lab is not.

A competitor can hire the AI team next quarter. They cannot compress seven years of GPCR data and 400 engineered cell lines into a funding round.

Capability
Antiverse
Generate
AbCellera
BigHat
Nabla
Generative de novo designFrom structure alone
Integrated dry + wet labOne loop, one roof
GPCR-exclusive training data7 years, single class
Proprietary GPCR cell lines400+, 20x expression
Published delivery commitmentA number, in public
Holds it Partial Does not Based on public claims. Verify before publishing.
Two corrections to the strategy doc, from the audit.

1. AbCellera. The doc says they "screen rather than design." In fact ABCL635 is a first-in-class antibody against NK3R, a GPCR, built with their GPCR and ion channel tech, already in Phase 1/2. A second is IND-enabling. They are further down the clinical path on GPCRs than Antiverse.

2. "Design not discovery" is taken. Nabla's homepage already reads "Designing Better Medicines" and claims integrated dry/wet-lab as one engine. BigHat claims the wet lab too. Both central reframes are live competitor positioning — which is why this section leads with the cell lines and the data, not the design language.
05The commitment

Six months.

Where discovery runs two to four years, six months changes what a pipeline can contain.

06Months, target to candidate
Industry standard
Antiverse
ScaleM0M12M24M36M48

"Six months from target to functional antibody candidates, or we talk about why."

Strategy §The six-month promise. The only claim in the category a partner can hold you to — which is exactly why it works.
06Proof

It has happened already.

Six partner programmes. Outcome-only one-pagers published while sign-offs are secured.

"The combination of generative design and a real GPCR wet lab is what this field has been missing. It's why I'm on this board."

Photo
Chuck Kunsch
Former MD, AbbVie Ventures

"I spent a career in biologics at Bayer. Antiverse reaches targets I was told to walk away from."

Photo
Lars Linden
Former VP Biologics, Bayer
Top 15 Pharma
Oncology, checkpoint
nM

Anti-PD-1 panel. Two antibodies advancing to preclinical.

One-pager
Top 20 Pharma
CNS, GPCR
4 mo

A receptor considered intractable. Delivered inside the commitment.

One-pager
Awaiting sign-off
Undisclosed
03

Three programmes pending publication permission.

Locked
As seen in
The Times GEN Drug Target Review DDW Manufacturing Chemist Sifted
Social proof, consolidated — strategy §Trust and §Interim trust signals. Three layers in one block: named advisors whose credential is the risk signal, anonymised outcome metrics, and the media wall. Kunsch and Linden are lifted out of the team carousel because both have run the diligence the reader is about to run. The locked card makes the NDA gap visible rather than hiding it — it reads as momentum and gives the BD owner a countdown.

What's on your list
that nobody could reach?

Submit it. A written feasibility assessment comes back within 48 hours.

Submit a target Partnership options
Close — strategy §Audience Architecture. Returns to the question the page opened on. Two routes, labelled by who they serve.